PMC:7558914 / 8728-10062 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"187","span":{"begin":40,"end":48},"obj":"Species"},{"id":"188","span":{"begin":116,"end":124},"obj":"Species"},{"id":"189","span":{"begin":168,"end":176},"obj":"Species"},{"id":"190","span":{"begin":1112,"end":1120},"obj":"Species"},{"id":"191","span":{"begin":1222,"end":1229},"obj":"Species"},{"id":"192","span":{"begin":217,"end":235},"obj":"Chemical"},{"id":"193","span":{"begin":239,"end":258},"obj":"Chemical"},{"id":"194","span":{"begin":278,"end":296},"obj":"Chemical"},{"id":"195","span":{"begin":302,"end":314},"obj":"Chemical"},{"id":"196","span":{"begin":318,"end":337},"obj":"Chemical"},{"id":"197","span":{"begin":362,"end":380},"obj":"Chemical"},{"id":"198","span":{"begin":382,"end":394},"obj":"Chemical"},{"id":"199","span":{"begin":400,"end":419},"obj":"Chemical"},{"id":"200","span":{"begin":421,"end":439},"obj":"Chemical"},{"id":"201","span":{"begin":486,"end":505},"obj":"Chemical"},{"id":"202","span":{"begin":650,"end":662},"obj":"Chemical"},{"id":"203","span":{"begin":772,"end":790},"obj":"Chemical"},{"id":"204","span":{"begin":805,"end":817},"obj":"Chemical"},{"id":"205","span":{"begin":839,"end":857},"obj":"Chemical"},{"id":"206","span":{"begin":913,"end":932},"obj":"Chemical"},{"id":"207","span":{"begin":967,"end":979},"obj":"Chemical"},{"id":"208","span":{"begin":999,"end":1010},"obj":"Chemical"},{"id":"209","span":{"begin":1071,"end":1089},"obj":"Chemical"},{"id":"210","span":{"begin":1150,"end":1169},"obj":"Chemical"},{"id":"211","span":{"begin":1204,"end":1214},"obj":"Chemical"},{"id":"212","span":{"begin":65,"end":84},"obj":"Disease"},{"id":"213","span":{"begin":157,"end":166},"obj":"Disease"}],"attributes":[{"id":"A187","pred":"tao:has_database_id","subj":"187","obj":"Tax:9606"},{"id":"A188","pred":"tao:has_database_id","subj":"188","obj":"Tax:9606"},{"id":"A189","pred":"tao:has_database_id","subj":"189","obj":"Tax:9606"},{"id":"A190","pred":"tao:has_database_id","subj":"190","obj":"Tax:9606"},{"id":"A191","pred":"tao:has_database_id","subj":"191","obj":"Tax:9606"},{"id":"A192","pred":"tao:has_database_id","subj":"192","obj":"MESH:D006886"},{"id":"A193","pred":"tao:has_database_id","subj":"193","obj":"MESH:C558899"},{"id":"A194","pred":"tao:has_database_id","subj":"194","obj":"MESH:D006886"},{"id":"A195","pred":"tao:has_database_id","subj":"195","obj":"MESH:D017963"},{"id":"A196","pred":"tao:has_database_id","subj":"196","obj":"MESH:C558899"},{"id":"A197","pred":"tao:has_database_id","subj":"197","obj":"MESH:D006886"},{"id":"A198","pred":"tao:has_database_id","subj":"198","obj":"MESH:D017963"},{"id":"A199","pred":"tao:has_database_id","subj":"199","obj":"MESH:C558899"},{"id":"A200","pred":"tao:has_database_id","subj":"200","obj":"MESH:D006886"},{"id":"A201","pred":"tao:has_database_id","subj":"201","obj":"MESH:C558899"},{"id":"A202","pred":"tao:has_database_id","subj":"202","obj":"MESH:D017963"},{"id":"A203","pred":"tao:has_database_id","subj":"203","obj":"MESH:D006886"},{"id":"A204","pred":"tao:has_database_id","subj":"204","obj":"MESH:D017963"},{"id":"A205","pred":"tao:has_database_id","subj":"205","obj":"MESH:D006886"},{"id":"A206","pred":"tao:has_database_id","subj":"206","obj":"MESH:C558899"},{"id":"A207","pred":"tao:has_database_id","subj":"207","obj":"MESH:D017963"},{"id":"A208","pred":"tao:has_database_id","subj":"208","obj":"MESH:D002738"},{"id":"A209","pred":"tao:has_database_id","subj":"209","obj":"MESH:D006886"},{"id":"A210","pred":"tao:has_database_id","subj":"210","obj":"MESH:C558899"},{"id":"A211","pred":"tao:has_database_id","subj":"211","obj":"MESH:C000606551"},{"id":"A212","pred":"tao:has_database_id","subj":"212","obj":"MESH:D012140"},{"id":"A213","pred":"tao:has_database_id","subj":"213","obj":"MESH:D011014"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Antiviral treatment was recommended for patients with mild upper respiratory illness with clinical risk factors and patients with mild, moderate, and severe pneumonia. Patients could be treated with monotherapy using hydroxychloroquine or lopinavir/ritonavir; dual therapy with hydroxychloroquine plus azithromycin or lopinavir/ritonavir; or triple therapy with hydroxychloroquine, azithromycin, and lopinavir/ritonavir. Hydroxychloroquine could be used in four different regimens, and lopinavir/ritonavir could be used in two different regimens, with varied dosages and duration of treatment—either a short (5-day) regimen or long (10-day) regimen. Azithromycin was recommended at the same dosage and duration of treatment. Protocols included the combination of all four hydroxychloroquine regimens with azithromycin. Regimens 1 and 3 of hydroxychloroquine were combined in dual therapy with the two regimens of lopinavir/ritonavir, which in turn were combined with azithromycin in triple therapy. Chloroquine 500 mg twice per day was recommended as an alternative when hydroxychloroquine was not available. In patients with three antiviral agents, lopinavir/ritonavir could be replaced with once-daily remdesivir if the patient was enrolled in a clinical trial. The dosage and durations of antiviral treatments are shown in Table 1."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T15","span":{"begin":65,"end":84},"obj":"Phenotype"},{"id":"T16","span":{"begin":157,"end":166},"obj":"Phenotype"}],"attributes":[{"id":"A15","pred":"hp_id","subj":"T15","obj":"http://purl.obolibrary.org/obo/HP_0002086"},{"id":"A16","pred":"hp_id","subj":"T16","obj":"http://purl.obolibrary.org/obo/HP_0002090"}],"text":"Antiviral treatment was recommended for patients with mild upper respiratory illness with clinical risk factors and patients with mild, moderate, and severe pneumonia. Patients could be treated with monotherapy using hydroxychloroquine or lopinavir/ritonavir; dual therapy with hydroxychloroquine plus azithromycin or lopinavir/ritonavir; or triple therapy with hydroxychloroquine, azithromycin, and lopinavir/ritonavir. Hydroxychloroquine could be used in four different regimens, and lopinavir/ritonavir could be used in two different regimens, with varied dosages and duration of treatment—either a short (5-day) regimen or long (10-day) regimen. Azithromycin was recommended at the same dosage and duration of treatment. Protocols included the combination of all four hydroxychloroquine regimens with azithromycin. Regimens 1 and 3 of hydroxychloroquine were combined in dual therapy with the two regimens of lopinavir/ritonavir, which in turn were combined with azithromycin in triple therapy. Chloroquine 500 mg twice per day was recommended as an alternative when hydroxychloroquine was not available. In patients with three antiviral agents, lopinavir/ritonavir could be replaced with once-daily remdesivir if the patient was enrolled in a clinical trial. The dosage and durations of antiviral treatments are shown in Table 1."}

{"project":"LitCovid-sentences","denotations":[{"id":"T55","span":{"begin":0,"end":167},"obj":"Sentence"},{"id":"T56","span":{"begin":168,"end":420},"obj":"Sentence"},{"id":"T57","span":{"begin":421,"end":649},"obj":"Sentence"},{"id":"T58","span":{"begin":650,"end":724},"obj":"Sentence"},{"id":"T59","span":{"begin":725,"end":818},"obj":"Sentence"},{"id":"T60","span":{"begin":819,"end":998},"obj":"Sentence"},{"id":"T61","span":{"begin":999,"end":1108},"obj":"Sentence"},{"id":"T62","span":{"begin":1109,"end":1263},"obj":"Sentence"},{"id":"T63","span":{"begin":1264,"end":1334},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Antiviral treatment was recommended for patients with mild upper respiratory illness with clinical risk factors and patients with mild, moderate, and severe pneumonia. Patients could be treated with monotherapy using hydroxychloroquine or lopinavir/ritonavir; dual therapy with hydroxychloroquine plus azithromycin or lopinavir/ritonavir; or triple therapy with hydroxychloroquine, azithromycin, and lopinavir/ritonavir. Hydroxychloroquine could be used in four different regimens, and lopinavir/ritonavir could be used in two different regimens, with varied dosages and duration of treatment—either a short (5-day) regimen or long (10-day) regimen. Azithromycin was recommended at the same dosage and duration of treatment. Protocols included the combination of all four hydroxychloroquine regimens with azithromycin. Regimens 1 and 3 of hydroxychloroquine were combined in dual therapy with the two regimens of lopinavir/ritonavir, which in turn were combined with azithromycin in triple therapy. Chloroquine 500 mg twice per day was recommended as an alternative when hydroxychloroquine was not available. In patients with three antiviral agents, lopinavir/ritonavir could be replaced with once-daily remdesivir if the patient was enrolled in a clinical trial. The dosage and durations of antiviral treatments are shown in Table 1."}